| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-13 11:45:11 UTC |
|---|
| Update Date | 2022-03-07 02:57:13 UTC |
|---|
| HMDB ID | HMDB0041873 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Dexketoprofen |
|---|
| Description | Dexketoprofen belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the action of a substance in the body called cyclo-oxygenase. Cyclo-oxygenase is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with Peripheral analgesic action it possesses central analgesic action. Dexketoprofen is a non-steroidal anti-inflammatory drug. It is manufactured by Menarini, under the tradename Keral. It is available in the UK, as dexketoprofen trometamol, as a prescription-only drug and in Latin America as Miracox, produced by Stein in Costa Rica. In Italy it is available as an over the counter-drug under the tradename Enantyum. In Lithuania it is available as over the counter-drug uder tradename Dolmen. |
|---|
| Structure | [H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1 InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/t11-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (+)-(S)-m-Benzoylhydratropic acid | ChEBI | | (+)-3-Benzoylhydratropic acid | ChEBI | | (+)-Ketoprofen | ChEBI | | (S)-3-Benzoyl-alpha-methylbenzeneacetic acid | ChEBI | | (S)-Ketoprofen | ChEBI | | (+)-(S)-m-Benzoylhydratropate | Generator | | (+)-3-Benzoylhydratropate | Generator | | (S)-3-Benzoyl-a-methylbenzeneacetate | Generator | | (S)-3-Benzoyl-a-methylbenzeneacetic acid | Generator | | (S)-3-Benzoyl-alpha-methylbenzeneacetate | Generator | | (S)-3-Benzoyl-α-methylbenzeneacetate | Generator | | (S)-3-Benzoyl-α-methylbenzeneacetic acid | Generator | | Badyket | HMDB | | Quiralam | HMDB | | Keral | HMDB | | Sympal | HMDB | | Ketesse | HMDB | | Enangel | HMDB | | Enantyum | HMDB | | Adolquir | HMDB | | Quirgel | HMDB | | Dexketoprofen trometamol | HMDB |
|
|---|
| Chemical Formula | C16H14O3 |
|---|
| Average Molecular Weight | 254.2806 |
|---|
| Monoisotopic Molecular Weight | 254.094294314 |
|---|
| IUPAC Name | (2S)-2-(3-benzoylphenyl)propanoic acid |
|---|
| Traditional Name | (+)-ketoprofen |
|---|
| CAS Registry Number | 22161-81-5 |
|---|
| SMILES | [H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/t11-/m0/s1 |
|---|
| InChI Key | DKYWVDODHFEZIM-NSHDSACASA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Benzophenones |
|---|
| Direct Parent | Benzophenones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzophenone
- Aryl-phenylketone
- Diphenylmethane
- 2-phenylpropanoic-acid
- Benzoyl
- Aryl ketone
- Ketone
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic oxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Organooxygen compound
- Organic oxide
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.88 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.1156 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 0.95 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2273.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 418.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 177.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 222.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 212.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 640.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 677.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 70.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1239.4 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 514.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1404.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 425.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 410.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 337.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 293.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 28.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized |
|---|
| General References | - Miranda HF, Romero MA, Puig MM: Antinociceptive and anti-exudative synergism between dexketoprofen and tramadol in a model of inflammatory pain in mice. Fundam Clin Pharmacol. 2012 Jun;26(3):373-82. doi: 10.1111/j.1472-8206.2010.00922.x. Epub 2011 Jan 25. [PubMed:22081874 ]
- Vera P, Zapata L, Gich I, Mancebo J, Betbese AJ: [Hemodynamic and antipyretic effects of paracetamol, metamizol and dexketoprofen in critical patients]. Med Intensiva. 2012 Dec;36(9):619-25. doi: 10.1016/j.medin.2012.02.003. Epub 2012 Mar 16. [PubMed:22425338 ]
- Porwal A, Mahajan AD, Oswal DS, Erram SS, Sheth DN, Balamurugan S, Kamat V, Enadle RP, Badadare A, Bhatnagar SK, Walvekar RS, Dhorepatil S, Naik RC, Basu I, Kshirsagar SN, Keny JV, Sengupta S: Efficacy and tolerability of fixed-dose combination of dexketoprofen and dicyclomine injection in acute renal colic. Pain Res Treat. 2012;2012:295926. doi: 10.1155/2012/295926. Epub 2012 Apr 23. [PubMed:22577544 ]
- Ozer AB, Erhan OL, Keles E, Demirel I, Bestas A, Gunduz G: Comparison of the effects of preoperative and intraoperative intravenous application of dexketoprofen on postoperative analgesia in septorhinoplasty patients: randomised double blind clinical trial. Eur Rev Med Pharmacol Sci. 2012 Nov;16(13):1828-33. [PubMed:23208967 ]
- Tunali Y, Akcil EF, Dilmen OK, Tutuncu AC, Koksal GM, Akbas S, Vehid H, Yentur E: Efficacy of intravenous paracetamol and dexketoprofen on postoperative pain and morphine consumption after a lumbar disk surgery. J Neurosurg Anesthesiol. 2013 Apr;25(2):143-7. doi: 10.1097/ANA.0b013e31827464af. [PubMed:23360885 ]
- Eken C, Serinken M, Elicabuk H, Uyanik E, Erdal M: Intravenous paracetamol versus dexketoprofen versus morphine in acute mechanical low back pain in the emergency department: a randomised double-blind controlled trial. Emerg Med J. 2014 Mar;31(3):177-81. doi: 10.1136/emermed-2012-201670. Epub 2013 Feb 13. [PubMed:23407378 ]
- Salman AE, Yetisir F, Yurekli B, Aksoy M, Yildirim M, Kilic M: The efficacy of the semi-blind approach of transversus abdominis plane block on postoperative analgesia in patients undergoing inguinal hernia repair: a prospective randomized double-blind study. Local Reg Anesth. 2013 Jan 18;6:1-7. doi: 10.2147/LRA.S38359. Print 2013. [PubMed:23630432 ]
- Allais G, Rolando S, Schiapparelli P, Airola G, Borgogno P, Mana O, Benedetto C: Frovatriptan plus dexketoprofen in the treatment of menstrually related migraine: an open study. Neurol Sci. 2013 May;34 Suppl 1:S179-81. doi: 10.1007/s10072-013-1390-0. [PubMed:23695075 ]
|
|---|